For Healthcare Professionals

A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)

clipboard-pencil

About the study

To evaluate the effectiveness, patient-reported outcomes (PROs) and safety of cladribine tablets in participants with relapsing forms of multiple sclerosis (RMS) including relapsing-remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (aSPMS),who transition to cladribine tablets after suboptimal response to any injectable disease-modifying drugs (DMDs) approved in the United States (US) for RMS in a real-world setting.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Male or female participants greater than or equal to (>=)18 years
  2. Signed informed consent
  3. Have diagnosis of RMS including RRMS and aSPMS and satisfy the approved indication for cladribine tablets as per United States Prescribing Information (USPI)
  4. Have time since diagnosis of RMS of at least 12 months
  5. Had received their last previous injectable disease-modifying drug (DMD) for at least 3 months
  6. Have decided to initiate treatment with cladribine tablets during routine clinical care
  7. Meet criteria as per the approved USPI
  8. Have access to a valid e-mail address
  9. In the opinion of the Investigator, experienced suboptimal response (lack of effectiveness, intolerability, poor adherence) to injectable DMD treatment

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Have been previously treated with cladribine in any dosing form
  2. Transitioning from previous injectable DMD solely for administrative reasons such as relocation
  3. Have comorbid conditions that preclude participation
  4. Have any clinical condition or medical history noted as contraindication on USPI
  5. Are currently participating in an interventional clinical trial
  6. Pregnant or breastfeeding women, women who plan to become pregnant or men whose partner plans to become pregnant during the cladribine treatment period

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Multiple Sclerosis

Age (in years)

18+

Participants needed

100

Est. Completion Date

Feb 21, 2026

Treatment type

Observational


Sponsor

EMD Serono

ClinicalTrials.gov identifier

NCT03933215

Study number

MS700568_0078

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.